Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease – authors' reply
Publisher： John Wiley & Sons Inc
E-ISSN： 1365-2036|42|7|940-941
ISSN： 0269-2813
Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.7, 2015-10, pp. : 940-941
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
